Protocol Ledger

NCT05604170 · Phase III · TERMINATED

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Interventional Phase III clinical trial protocol NCT05604170 sponsored by Marinus Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-16 Enrollment: 117 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05604170
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)117 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05604170
Protocol FieldVerified Registry Value
NCT IdentifierNCT05604170
Consolidated Lead SponsorMarinus Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment117 participants (ACTUAL)
Registered Start Date2022-05-16
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI